OTCMKTS:AVDX - Avant Diagnostics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$0.01
Today's RangeN/A
52-Week Range$0.0001 - $0.0784
Volume1,471 shs
Average Volume6,283 shs
Market Capitalization$3.37 million
P/E RatioN/A
Dividend YieldN/A
Avant Diagnostics, Inc., a molecular diagnostic company, focuses on the development and commercialization of proprietary diagnostic tests that provide information for physicians and patients in the areas of cancers. It offers OvaDx, a noninvasive proteomics diagnostic screening test for the early detection of ovarian cancer; and MSPrecise, a DNA sequencing assay for the identification of patients with relapsing-remitting multiple sclerosis at first clinical presentation. The company is based in Washington, District of Columbia.

Receive AVDX News and Ratings via Email

Sign-up to receive the latest news and ratings for AVDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Miscellaneous equipment rental & leasing
Current SymbolOTCMKTS:AVDX
Previous Symbol


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$110,000.00
Price / Sales0.00
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding Shares336,960,000
Market Cap$3.37 million
OptionableNot Optionable

Avant Diagnostics (OTCMKTS:AVDX) Frequently Asked Questions

What is Avant Diagnostics' stock symbol?

Avant Diagnostics trades on the OTCMKTS under the ticker symbol "AVDX."

Has Avant Diagnostics been receiving favorable news coverage?

Media headlines about AVDX stock have been trending somewhat positive recently, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Avant Diagnostics earned a media sentiment score of 0.6 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future.

Who are some of Avant Diagnostics' key competitors?

Who are Avant Diagnostics' key executives?

Avant Diagnostics' management team includes the folowing people:
  • Mr. Jeffrey M. Busch, Exec. Chairman (Age 58)
  • Dr. Michael I. Ruxin, Pres, CEO & Director (Age 72)
  • Mr. Scott VanderMeer, Interim Chief Financial Officer (Age 32)
  • Dr. Glenn D. Hoke Ph.D., Chief Scientific Officer
  • Ms. Rene A. Schena, Chairman & CEO of Arrayit Corp. (Age 55)

How do I buy shares of Avant Diagnostics?

Shares of AVDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How big of a company is Avant Diagnostics?

Avant Diagnostics has a market capitalization of $3.37 million and generates $110,000.00 in revenue each year. Avant Diagnostics employs 1 workers across the globe.

What is Avant Diagnostics' official website?

The official website for Avant Diagnostics is http://www.avantdiagnostics.com.

How can I contact Avant Diagnostics?

Avant Diagnostics' mailing address is 1050 30TH STREET NW SUITE 107, WASHINGTON DC, 20007. The company can be reached via phone at 708-710-9200 or via email at [email protected]

MarketBeat Community Rating for Avant Diagnostics (OTCMKTS AVDX)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  27 (Vote Outperform)
Underperform Votes:  35 (Vote Underperform)
Total Votes:  62
MarketBeat's community ratings are surveys of what our community members think about Avant Diagnostics and other stocks. Vote "Outperform" if you believe AVDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel